PRODUCTS SOLD ON PEPTIDESLABEU.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
PRODUCTS SOLD ON PEPTIDESLABEU.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
€66.00
SLU-PP 332 EU – Buy Online | In Stock & Ready to Ship
Buy SLU-PP 332 in Europe with fast shipping and guaranteed ≥99% purity — verified with COA and HPLC documentation. A trusted choice for peptides EU research teams rely on, with no customs delays or lengthy international wait times. Whether you’re searching for SLU-PP 332 Europe suppliers, looking to buy SLU-PP 332 in the EU, or sourcing peptides Europe-wide, we have you covered. Research teams across the EU can count on consistent stock, rapid fulfilment and full batch documentation every time.
For research use only. Not intended for human or veterinary use.
SLU-PP-332 is a synthetic small molecule ERR (Estrogen-Related Receptor) agonist, available to buy in Europe for laboratory research into mitochondrial biogenesis, oxidative metabolism, skeletal muscle fibre type biology, and nuclear receptor pharmacology.
Laboratories and research institutions across the EU can order verified, research-grade SLU-PP-332 with fast international dispatch to Europe, full batch documentation, and ≥99% purity confirmed by HPLC and Mass Spectrometry.
✅ ≥99% Purity — HPLC & Mass Spectrometry Verified
✅ Batch-Specific Certificate of Analysis (CoA)
✅ High-Purity Small Molecule | GMP Manufactured
✅ Fast Dispatch to EU & Europe | Tracked Shipping
SLU-PP-332 is a synthetic small molecule pan-agonist of the Estrogen-Related Receptor (ERR) family — specifically activating all three ERR subtypes: ERRα, ERRβ, and ERRγ. Developed at Saint Louis University, it represents one of the first well-characterised, potent pan-ERR agonists available as a research tool and has rapidly become a compound of significant interest in metabolic biology, mitochondrial research, and exercise physiology.
The Estrogen-Related Receptors are orphan nuclear receptors — transcription factors structurally related to oestrogen receptors but not activated by oestrogens — that act as master regulators of oxidative metabolism and mitochondrial function. ERRα in particular is one of the most important transcriptional regulators of mitochondrial biogenesis and fatty acid oxidation, working in concert with the PGC-1α coactivator to drive the gene expression programmes underlying aerobic energy production in metabolically active tissues including skeletal muscle, heart, and brown adipose tissue.
SLU-PP-332’s pan-ERR agonism positions it as a research tool for studying the coordinated activation of all three ERR subtypes simultaneously — providing insights into the collective role of ERR family signalling in oxidative metabolism regulation that subtype-selective tools cannot provide. Its ability to drive a transcriptional programme resembling the adaptations produced by endurance exercise training — including mitochondrial biogenesis, oxidative fibre type shifts, and enhanced fatty acid oxidation capacity — has generated significant research interest in its utility as a pharmacological model of exercise-like metabolic adaptation, earning it attention in the European research community as a so-called “exercise mimetic” research compound.
In laboratory settings, SLU-PP-332 is studied primarily as a pan-ERR agonist driving oxidative metabolism and mitochondrial biology programmes, with research applications extending into metabolic disease models, muscle physiology, and cardiac biology. EU and European researchers working with SLU-PP-332 typically focus on:
All research applications are for in vitro and pre-clinical use only.
SLU-PP-332 has generated a rapidly growing research literature since its characterisation — with pre-clinical studies establishing its pan-ERR agonist pharmacology and documenting a broad range of metabolic, mitochondrial, and tissue-specific biological effects.
Pan-ERR agonism characterisation: The foundational pharmacology studies of SLU-PP-332 characterised its binding and activation of ERRα, ERRβ, and ERRγ — establishing it as the first well-characterised pan-ERR agonist and documenting its potency and selectivity profile relative to oestrogen receptors and other nuclear receptors. These studies established SLU-PP-332 as the reference compound for pan-ERR pharmacology research.
Exercise mimetic biology: A landmark pre-clinical study demonstrated that SLU-PP-332 administration in rodent models drove skeletal muscle gene expression changes resembling those produced by endurance exercise training — including upregulation of oxidative metabolism genes, mitochondrial biogenesis markers, and Type I fibre-associated transcriptional programmes. Treated animals showed improved endurance performance parameters compared to controls — findings that established SLU-PP-332 as a pharmacological exercise mimetic research tool of significant interest.
Mitochondrial biogenesis: Studies have documented SLU-PP-332-driven upregulation of mitochondrial biogenesis gene networks in skeletal muscle and cardiac tissue — including PGC-1α targets, mitochondrial transcription factor A (TFAM), and components of the electron transport chain — with corresponding increases in mitochondrial content markers. These findings have characterised the transcriptional mechanisms linking ERR activation to mitochondrial expansion.
Obesity and metabolic research: Pre-clinical studies in dietary obesity models have documented SLU-PP-332 effects on body composition — including reductions in adiposity and improvements in metabolic parameters — attributed to ERR-driven increases in oxidative metabolism capacity and fatty acid utilisation. These findings have positioned SLU-PP-332 as a research tool for studying pharmacological metabolic reprogramming in obesity biology.
Cardiac biology: Research has examined SLU-PP-332 in cardiac models — documenting ERR agonism effects on cardiac mitochondrial gene expression, energy substrate metabolism, and cardiomyocyte function under normal and stressed conditions. Given the heart’s dependence on oxidative metabolism and high ERR expression, these findings have established a cardiac research application for SLU-PP-332 alongside its skeletal muscle profile.
Heart failure models: Pre-clinical studies have examined SLU-PP-332 in heart failure models — with findings suggesting ERR agonism supports cardiac energetic function, reduces maladaptive remodelling markers, and improves functional parameters in failing heart models. This line of research reflects the broader interest in ERR-driven metabolic support as a cardioprotective strategy.
Ageing and muscle biology: Studies have examined SLU-PP-332 in aged animal models — characterising its ability to partially restore oxidative capacity, mitochondrial density, and exercise performance parameters in aged skeletal muscle — contributing to understanding of how ERR signalling decline contributes to age-related metabolic deterioration and how pharmacological ERR activation might probe these mechanisms.
| Compound | Type | Target | Key Research Application |
|---|---|---|---|
| SLU-PP-332 | Pan-ERR agonist | ERRα + ERRβ + ERRγ | Mitochondrial biogenesis, exercise mimetic, oxidative metabolism |
| GSK4716 | ERRβ/γ selective agonist | ERRβ + ERRγ | Subtype-selective ERR pharmacology |
| DY131 | ERRβ/γ agonist | ERRβ + ERRγ | Comparative ERRβ/γ biology |
| XCT790 | ERRα inverse agonist | ERRα | ERRα inhibition, metabolic suppression research |
| GW501516 (Cardarine) | PPARδ agonist | PPARδ | Fatty acid oxidation, endurance biology — distinct pathway |
| AICAR | AMPK activator | AMPK | Exercise mimetic — AMPK pathway, distinct mechanism |
| Resveratrol | SIRT1/PGC-1α activator | SIRT1 / PGC-1α | Mitochondrial biology — upstream ERR coactivator pathway |
Every order of SLU-PP-332 dispatched to EU and European research institutions includes:
Yes. We supply research-grade SLU-PP-332 with fast tracked international dispatch to all EU member states and wider European destinations. All orders include full batch documentation and are packaged to maintain compound integrity throughout transit. SLU-PP-332 is supplied strictly for laboratory research use only.
Estrogen-Related Receptors (ERRα, ERRβ, ERRγ) are orphan nuclear receptors — transcription factors that share structural similarity with oestrogen receptors but are not activated by oestrogens and have no known endogenous hormonal ligand. They function as master regulators of oxidative metabolism — binding to ERR response elements in the promoters of genes encoding mitochondrial biogenesis, fatty acid oxidation, oxidative phosphorylation, and tricarboxylic acid cycle components. ERRα in particular is one of the most important transcriptional regulators of cellular energy metabolism, working in close partnership with the PGC-1α coactivator to drive the gene expression programmes underlying aerobic energy production in metabolically demanding tissues.
Endurance exercise training produces a well-characterised set of skeletal muscle adaptations — including mitochondrial biogenesis, shifts toward oxidative slow-twitch fibre characteristics, increased fatty acid oxidation capacity, and improved fatigue resistance — driven largely by PGC-1α/ERRα transcriptional co-activation. SLU-PP-332’s pan-ERR agonism activates this same transcriptional programme pharmacologically — producing gene expression and phenotypic changes in skeletal muscle that closely resemble endurance training adaptations without the requirement for physical exercise. This makes it a research tool for studying the molecular mechanisms of exercise adaptation in systems where physical training is not feasible, and for probing whether pharmacological activation of exercise-associated pathways can reproduce the metabolic benefits of training.
Both SLU-PP-332 and GW501516 are studied in the context of oxidative metabolism and exercise mimetic biology, but they act through entirely distinct receptor mechanisms. GW501516 is a PPARδ agonist — activating the Peroxisome Proliferator-Activated Receptor delta pathway to drive fatty acid oxidation gene expression. SLU-PP-332 is a pan-ERR agonist — activating all three Estrogen-Related Receptor subtypes to drive a broader mitochondrial biogenesis and oxidative metabolism transcriptional programme. The two compounds are studied as complementary tools for examining different nuclear receptor pathways converging on oxidative metabolism — with distinct downstream gene networks and tissue distribution profiles.
PGC-1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha) is the master regulator of mitochondrial biogenesis — a transcriptional coactivator that does not bind DNA directly but amplifies the activity of transcription factors including ERRα. ERRα is one of PGC-1α’s primary transcriptional partners — with PGC-1α binding to and dramatically potentiating ERRα transcriptional activity at mitochondrial biogenesis gene promoters. SLU-PP-332’s ERRα agonism therefore directly engages the PGC-1α/ERRα co-regulatory axis — making it a research tool for studying this central node in mitochondrial biogenesis regulation and how pharmacological ERR activation interacts with PGC-1α coactivator availability.
SLU-PP-332 is a small molecule compound with limited aqueous solubility. It is typically solubilised in DMSO for stock solution preparation, followed by dilution into aqueous buffer or cell culture medium at working concentrations. Standard small molecule handling protocols apply — prepare concentrated DMSO stocks, store at -20°C protected from light and moisture, and ensure final DMSO concentrations in biological assays are within established tolerance limits for your experimental system. Refer to the included handling protocol for specific solubility and preparation guidance.
Orders are dispatched promptly via tracked international courier. Delivery to EU and European destinations typically takes 3–7 working days depending on location, with packaging designed to maintain compound stability throughout transit.
| Parameter | Detail |
|---|---|
| Type | Synthetic Small Molecule Pan-ERR Agonist |
| Targets | ERRα + ERRβ + ERRγ (Estrogen-Related Receptors) |
| Primary Research Interest | Mitochondrial biogenesis, oxidative metabolism, exercise mimetic biology |
| Purity | ≥99% |
| Verification | HPLC & Mass Spectrometry |
| Form | Small Molecule Powder |
| Solubility | DMSO — dilute to working concentration in aqueous buffer |
| Storage | -20°C, protected from light and moisture |
| Intended Use | Research use only |
SLU-PP-332 is supplied exclusively for legitimate scientific research conducted within licensed laboratory environments. This product is not approved for human consumption, self-administration, or any therapeutic, clinical, or veterinary application. It must be handled solely by qualified researchers in compliance with applicable EU regulations, national legislation, and institutional ethics guidelines. By purchasing, you confirm this compound will be used exclusively for approved in vitro or pre-clinical research purposes.
Receive News
